Cat. No.: HY-15128

9-cis-Retinoic acid

(Synonyms: Alitretinoin)

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities.

For research use only. We do not sell to patients.

Purity: 99.92%
CAS No.: 5300-03-8
Formula: C₂₀H₂₈O₂
Molecular Weight:300.44

Storage:

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

9-cis-Retinoic acid Chemical Structure

CAS No.: 5300-03-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Human Endogenous Metabolite

All RAR/RXR Isoforms :

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CV-1	EC₅₀	0.2 μM Compound: 36, 9cRA	Transactivation of Gal4-LBD fused mouse RXRalpha (218 to 467) transfected in african green monkey CV1 cells assessed as luciferase activity at after 6 hrs by Dual-light chemiluminescent assay Transactivation of Gal4-LBD fused mouse RXRalpha (218 to 467) transfected in african green monkey CV1 cells assessed as luciferase activity at after 6 hrs by Dual-light chemiluminescent assay	[PMID: 19216008]
CV-1	EC₅₀	1.5 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha	[PMID: 11428923]
CV-1	EC₅₀	100 nM Compound: 9-cis-RA	Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	124 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma	[PMID: 12482435]
CV-1	EC₅₀	128 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta	[PMID: 12482435]
CV-1	EC₅₀	140 nM Compound: 9-cis-RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	140 nM Compound: 9-cis-RA	Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	191 nM Compound: 9-cis-RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	191 nM Compound: 9-cis-RA	Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	195 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha	[PMID: 12482435]
CV-1	EC₅₀	200 nM Compound: 9-cis-RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	200 nM Compound: 9-cis-RA	Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	200 nM Compound: 9-cis-RA	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta	[PMID: 8709094]
CV-1	EC₅₀	21 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR alpha Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR alpha	[PMID: 11428923]
CV-1	EC₅₀	219 nM Compound: 9-cis-RA	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma	[PMID: 8709094]
CV-1	EC₅₀	220 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha	[PMID: 12482435]
CV-1	EC₅₀	250 nM Compound: 9-cis-RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	29 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR beta Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR beta	[PMID: 11428923]
CV-1	EC₅₀	29 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta	[PMID: 12482435]
CV-1	EC₅₀	3 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR beta Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR beta	[PMID: 11428923]
CV-1	EC₅₀	304 nM Compound: 9-cis-RA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha	[PMID: 8709094]
CV-1	EC₅₀	316 nM Compound: 9-cis-RA	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha	[PMID: 8709094]
CV-1	EC₅₀	4 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR gamma Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR gamma	[PMID: 11428923]
CV-1	EC₅₀	4.5 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma	[PMID: 11428923]
CV-1	EC₅₀	45 nM Compound: 9-cis-RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	45 nM Compound: 9-cis-RA	Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	50 nM Compound: 9-cis-RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	50 nM Compound: 9-cis RA	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma	[PMID: 12482435]
CV-1	EC₅₀	50 nM Compound: 9-cis-RA	Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	52 nM Compound: 9-cis-RA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta	[PMID: 8709094]
CV-1	EC₅₀	74 nM Compound: 9-cis-RA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma	[PMID: 8709094]
HEK293	EC₅₀	10 nM Compound: 9CisRA	Agonist activity at human RXRalpha expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human RXRalpha expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
HEK293	EC₅₀	120 nM Compound: 9cRA	Agonist activity at Gal4-fused human RXR-alpha expressed in HEK293 cells assessed as receptor-mediated transcriptional activity treated 24 hrs after transfection measured 48 hrs post-transfection by dual luciferase reporter assay Agonist activity at Gal4-fused human RXR-alpha expressed in HEK293 cells assessed as receptor-mediated transcriptional activity treated 24 hrs after transfection measured 48 hrs post-transfection by dual luciferase reporter assay	[PMID: 24801499]
HEK-293T	EC₅₀	1.09 μM Compound: 13	Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay	[PMID: 28169169]
HEK-293T	EC₅₀	1.73 μM Compound: 13	Partial agonist activity at recombinant human GAL4-DBD-fused LXRbeta-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay Partial agonist activity at recombinant human GAL4-DBD-fused LXRbeta-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay	[PMID: 28169169]
HL-60	EC₅₀	2 nM Compound: 9-cis RA	Transglutaminase activity in HL-60 cdm-1 cells Transglutaminase activity in HL-60 cdm-1 cells	[PMID: 7636843]
HL-60	EC₅₀	2 nM Compound: 9-cis-RA	Induction of transglutaminase (TGase) activity in HL-60 cells Induction of transglutaminase (TGase) activity in HL-60 cells	[PMID: 8784454]

In Vitro

9-cis-Retinoic acid (1-10 μM; 0-5 days; CA 9-22 and NA cells) treatment significantly decreases proliferation in a dose-dependent manner in CA 9-22 and NA cells^[1].
9-cis-Retinoic acid (1 μM; 24 hours) treatment significantly increases PPARγ functional activity by >200% in CA 9-22 and NA aerodigestive cells^[1].
9-cis-Retinoic acid treatment results in the formation of a nuclear PPARγ-RXRα heterodimer supershift complex in CA 9-22 cells^[1].
9-cis-Retinoic acid inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma (CTCL) in a dose-dependent and time-dependent manner. 9-cis-Retinoic acid also induces G0/G1 cell cycle arrest by downregulation of cyclin D1. 9-cis-Retinoic acid significantly decreases phosphorylation of JAK1, STAT3, and STAT5 and downregulated Bcl-xL and cyclin D1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

CA 9-22 and NA cells
Concentration:

1 μM, 10 μM
Incubation Time:

0 day, 1 day, 3 days, 5 days
Result:

Significantly decreased proliferation.

In Vivo

9-cis-Retinoic acid (1 mg/kg; intravenous injection; daily; for 10 days; male C57BL/6J mice) treatment significantly decreases the serum ALT and AST level, alleviates hepatic necrosis of the bile duct ligation (BDL)-mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6J mice (6-8 weeks; 19-22 g) treatment with bile duct ligated^[3]
Dosage:

1 mg/kg
Administration:

Intravenous injection; daily; for 10 days
Result:

Significantly decreased the serum ALT and AST level, alleviated hepatic necrosis.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 5300-03-8
Appearance Solid
Molecular Weight 300.44
Formula C₂₀H₂₈O₂
Color White to yellow
SMILES

CC(/C=C/C(C(C)(CCC1)C)=C1C)=C/C=C/C(C)=C/C(O)=O
Synonyms

Alitretinoin
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (6)

All WBOthersCell Imaging/Staining

Sort by:

Journal Impact Factor

Nat Commun

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. [Abstract]

2024 Jun 18;15(1):5183. PMID: 38890370
Phytomedicine

2025 Dec 28.
Mar Drugs

Synthesis and Biological Evaluation of Marine-Inspired Benzothiazole Derivatives as Retinoid X Receptor-α Antagonists with Anti-Cancer Activities. [Abstract]

2025 Sep 21;23(9):368. PMID: 41003337
J Biol Chem

A cell-based assay for retinaldehyde dehydrogenase activity: Retinoid quantification as an alternative to current fluorescence-based approaches. [Abstract]

2026 Jan 29;302(3):111211. PMID: 41617028

9-cis-Retinoic acid purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2026 Jan 29;302(3):111211. [Abstract]

MutuDC1940 cells were treated for 20 h with 1 μM 9-cis-Retinoic acid (9cRA), then subjected to Western blotting.

9-cis-Retinoic acid purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2026 Jan 29;302(3):111211. [Abstract]

MutuDC1940 cells were treated for 20 h with 1 μM 9-cis-Retinoic acid (9cRA), then assayed for RALDH activity in the suspension cell format, utilising the indicated RAL concentrations for 20 min.

9-cis-Retinoic acid purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2026 Jan 29;302(3):111211. [Abstract]

mutuDC1940 cells were treated with 1 μM 9-cis-Retinoic acid (9cRA) for 20 hours (with or without), and then AldeRed retention assays were performed with or without 1 μM Win446 or 10 μM DEAB.
Cell Press Blue

2026 Apr 22.
Research Square Preprint

2024 Aug 21.

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (83.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3285 mL

16.6423 mL

33.2845 mL

5 mM

0.6657 mL

3.3285 mL

6.6569 mL

10 mM

0.3328 mL

1.6642 mL

3.3285 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Raul Rosas, et al. Retinoids Augment Thiazolidinedione PPARγ Activation in Oral Cancer Cells. Anticancer Res. 2020 Jun;40(6):3071-3080. [Content Brief]

[2]. Hua Yang, et al. Effects of 9-cis-retinoic Acid on the Proliferation and Apoptosis of Cutaneous T-cell Lymphoma Cells. Anticancer Drugs. 2019 Jan;30(1):56-64. [Content Brief]

[3]. Zhiqing Yuan, et al. 9-cis-retinoic Acid Elevates MRP3 Expression by Inhibiting Sumoylation of RXRα to Alleviate Cholestatic Liver Injury. Biochem Biophys Res Commun. 2018 Sep 3;503(1):188-194. [Content Brief]

[4]. V M Manzano, et al. Human Renal Mesangial Cells Are a Target for the Anti-Inflammatory Action of 9-cis Retinoic Acid. Br J Pharmacol. 2000 Dec;131(8):1673-83. [Content Brief]

[5]. Gro H Mathisen, et al. Delayed Translocation of NGFI-B/RXR in Glutamate Stimulated Neurons Allows Late Protection by 9-cis Retinoic Acid. Biochem Biophys Res Commun. 2011 Oct 14;414(1):90-5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3285 mL	16.6423 mL	33.2845 mL	83.2113 mL
	5 mM	0.6657 mL	3.3285 mL	6.6569 mL	16.6423 mL
	10 mM	0.3328 mL	1.6642 mL	3.3285 mL	8.3211 mL
	15 mM	0.2219 mL	1.1095 mL	2.2190 mL	5.5474 mL
	20 mM	0.1664 mL	0.8321 mL	1.6642 mL	4.1606 mL
	25 mM	0.1331 mL	0.6657 mL	1.3314 mL	3.3285 mL
	30 mM	0.1109 mL	0.5547 mL	1.1095 mL	2.7737 mL
	40 mM	0.0832 mL	0.4161 mL	0.8321 mL	2.0803 mL
	50 mM	0.0666 mL	0.3328 mL	0.6657 mL	1.6642 mL
	60 mM	0.0555 mL	0.2774 mL	0.5547 mL	1.3869 mL
	80 mM	0.0416 mL	0.2080 mL	0.4161 mL	1.0401 mL

9-cis-Retinoic acid

6 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

9-cis-Retinoic acid

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) 9-cis-Retinoic acid

All RAR/RXR Isoforms

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

9-cis-Retinoic acid

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) 9-cis-Retinoic acid

All RAR/RXR Isoforms

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

9-cis-Retinoic acid Related Classifications

HY-15128 Related Classifications